Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

VANDA PHARMACEUTICALS INC. (VNDA)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Vanda Pharmaceuticals : Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum(TM) for the Treatment of Schizophrenia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:06pm CEST

WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum(TM) (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum(TM) MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptum(TM) MAA on November 9, 2017.

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

About Fanapt(®)

For full U.S. Prescribing Information for Fanapt(®), including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

View original content:http://www.prnewswire.com/news-releases/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-agency-on-fanaptum-for-the-treatment-of-schizophrenia-300554039.html

SOURCE Vanda Pharmaceuticals Inc.


© PRNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
10/04VANDA PHARMACEUTICALS INC. : Other Events (form 8-K)
AQ
10/01VANDA PHARMACEUTICALS : Announces Participation at Oppenheimer and Cantor Fitzge..
AQ
09/26VANDA PHARMACEUTICALS : Announces Participation at Oppenheimer and Cantor Fitzge..
PR
09/20VANDA PHARMACEUTICALS : Announces Listing of a New HETLIOZ® Patent in the FDA Or..
PR
09/14VANDA PHARMACEUTICALS INC. : - HETLIOZ Driving Study Demonstrates No Impairment ..
AQ
09/13VANDA PHARMACEUTICALS : HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Imp..
PR
09/04VANDA PHARMACEUTICALS : Announces Participation at September 2018 Investor Confe..
PR
08/14VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
08/14VANDA PHARMACEUTICALS : Wins Denial of Petition For Rehearing on Fanapt®
PR
08/14BIOCENTURY - MANAGEMENT TRACKS : FDA, Allergan
AQ
More news
News from SeekingAlpha
10/14WEEK 42 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
10/07WEEK 41 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
09/21Vanda announces listing of a new HETLIOZ patent in the FDA orange book 
09/17VANDA : A Grower Operating At An Inflection 
09/13Vanda Pharmaceuticals +1.1% as Stifel starts at Buy